Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.46 |
| ▸ | CIT | O14578 | 3/20 | 0.46 |
| ▸ | GSK3B | P49841 | 3/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.46 |
| ▸ | PRKACA | P17612 | 2/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.46 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.46 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | PRKCB | P05771 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.46 |
| ▸ | MARK3 | P27448 | 1/20 | 0.46 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4446202 | 1.00 | ROCK2 (0.46) | ROCK2ROCK1CITGSK3BPRKD3 | |
| SCHEMBL2847238 | 1.00 | ROCK2 (0.46) | ROCK2ROCK1CITGSK3BPRKD3 | |
| Bromide SCHEMBL5956696 | 0.99 | ROCK2 (0.45) | ROCK2ROCK1CITGSK3BPRKD3 | |
| SCHEMBL4441669 | 0.91 | ROCK2 (0.47) | ROCK2ROCK1CITGSK3BPRKD3 | |
| SCHEMBL4441679 | 0.91 | ROCK2 (0.47) | ROCK2ROCK1CITGSK3BPRKD3 | |
| SCHEMBL4445752 | 0.91 | ROCK2 (0.47) | ROCK2ROCK1CITGSK3BPRKD3 | |
| SCHEMBL2858444 | 0.89 | JAK2 (0.48) | ROCK2ROCK1CITGSK3BPRKD3 | |
| SCHEMBL4438534 | 0.89 | JAK2 (0.48) | ROCK2ROCK1CITGSK3BPRKD3 | |
| SCHEMBL2858448 | 0.89 | JAK2 (0.48) | ROCK2ROCK1CITGSK3BPRKD3 | |
| Bromide SCHEMBL5956520 | 0.88 | JAK2 (0.48) | ROCK2ROCK1CITGSK3BPRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1270570-B1 | AMIDE COMPOUNDS AND USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2006-05-31 | — | — | EP | claimed |
| US-6933305-B2 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-08-23 | — | — | US | claimed |
| US-20030158413-A1 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-21 | — | — | US | claimed |
| EP-1270570-A1 | AMIDE COMPOUNDS AND USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-01-02 | — | — | EP | claimed |
| US-7696194-B2 | treating with fasudil hydrochloride; enzyme inhibitor of Rho kinase; promoting regeneration of an optic nerve cell | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2010-04-13 | — | — | US | disclosed |
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | UNITED THERAPEUTICS CORPORATION | 2009-02-05 | — | — | US | disclosed |
| WO-2008049000-A2 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | UNITED THERAPEUTICS CORPORATION (US) | 2008-04-24 | — | — | WO | disclosed |
| US-7109208-B2 | Visual function disorder improving agents | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2006-09-19 | — | — | US | disclosed |
| US-20060148852-A1 | Visual function disorder improving agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1270570-B1 | AMIDE COMPOUNDS AND USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-6933305-B2 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-08-23 | — | — | US | disclosed |
| US-20040106646-A1 | Visual function disorder improving agents | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| EP-1378247-A1 | VISUAL FUNCTION IMPROVING AGENTS | Senju Pharmaceutical Co., Ltd. (JP) | 2004-01-07 | — | — | EP | disclosed |
| US-20030158413-A1 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1270570-A1 | AMIDE COMPOUNDS AND USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158413-A1 | Amide compounds and use thereof | ROCK2, ROCK1, RHOT2 | ROCK2 1/4885ROCK1 2/4885CIT 4/4885 |
| US-20040106646-A1 | Visual function disorder improving agents | ARHGDIA, GAP43, RHOT2 | ROCK2 41/4885ROCK1 25/4885CIT 129/4885 |
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | ROCK1, ROCK2, RHOA | ROCK2 2/4885ROCK1 1/4885CIT 9/4885 |
| US-20060148852-A1 | Visual function disorder improving agents | GAP43, ARHGDIA, RHOT2 | ROCK2 56/4885ROCK1 33/4885CIT 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.